Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$162.02M+24.8%
Altimmune logo
AltimmuneALT
$335.63M+113%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$608.24M-29.8%
Wave Life Sciences logo
Wave Life SciencesWVE
$558.32M+121%
Arrowhead Research logo
Arrowhead ResearchARWR
$2.27B+44.2%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2026 and December 31, 2025; 2,369,797 shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, par value $0.0001 per share authorized: 200,000,000 shares at June 30, 2026 and December 31, 2025; 23,093,974 and 22,842,073 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively22
Additional paid-in-capital2,765,7102,692,280
Accumulated other comprehensive income808873
Accumulated deficit(2,242,796)(2,090,466)
Total stockholders’ equity523,724602,689
Total liabilities and stockholders’ equity$1,244,645$1,259,589

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s total liabilities & equity?
Madrigal Pharmaceuticals, Inc. (MDGL) reported total liabilities & equity of $1.24B in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s total liabilities & equity increased by 22.6% year-over-year, from $1.02B to $1.24B.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 34.4% compound annual growth rate (CAGR), from $287M to $1.26B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude